Ontario Cancer Institute and the Campbell Family Institute for Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Radiation Medicine Program, STTARR Innovation Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Radiation Medicine Program, STTARR Innovation Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):722-8. doi: 10.1016/j.ijrobp.2014.03.048. Epub 2014 May 24.
To investigate the outcome of suppression of the renin angiotensin system using captopril combined with an antioxidant (Eukarion [EUK]-207) for mitigation of radiation-induced lung damage in rats.
The thoracic cavity of female Sprague-Dawley rats was irradiated with a single dose of 11 Gy. Treatment with captopril at a dose of 40 mg/kg/d in drinking water and EUK-207 given by subcutaneous injection (8 mg/kg daily) was started 1 week after irradiation (PI) and continuing until 14 weeks PI. Breathing rate was monitored until the rats were killed at 32 weeks PI, when lung fibrosis was assessed by lung hydroxyproline content. Lung levels of the cytokine transforming growth factor-β1 and macrophage activation were analyzed by immunohistochemistry. Oxidative DNA damage was assessed by 8-hydroxy-2-deoxyguanosine levels, and lipid peroxidation was measured by a T-BARS assay.
The increase in breathing rate in the irradiated rats was significantly reduced by the drug treatments. The drug treatment also significantly decreased the hydroxyproline content, 8-hydroxy-2-deoxyguanosine and malondialdehyde levels, and levels of activated macrophages and the cytokine transforming growth factor-β1 at 32 weeks. Almost complete mitigation of these radiation effects was observed by combining captopril and EUK-207.
Captopril and EUK-207 can provide mitigation of radiation-induced lung damage out to at least 32 weeks PI after treatment given 1-14 weeks PI. Overall the combination of captopril and EUK-207 was more effective than the individual drugs used alone.
研究血管紧张素转换酶抑制剂卡托普利联合抗氧化剂(Eukarion [EUK]-207)抑制肾素血管紧张素系统对减轻大鼠放射性肺损伤的作用。
雌性 Sprague-Dawley 大鼠的胸腔接受单次 11 Gy 照射。卡托普利以 40mg/kg/d 的剂量加入饮用水中,EUK-207 经皮下注射(每天 8mg/kg),在照射后 1 周(PI)开始治疗,持续至 14 周 PI。在 32 周 PI 处死大鼠之前监测呼吸频率,通过肺羟脯氨酸含量评估肺纤维化。通过免疫组织化学分析细胞因子转化生长因子-β1 和巨噬细胞激活的肺水平。通过 8-羟基-2-脱氧鸟苷水平评估氧化 DNA 损伤,通过 T-BARS 测定法测量脂质过氧化。
药物治疗显著降低了照射大鼠呼吸频率的增加。药物治疗还显著降低了 32 周时羟脯氨酸含量、8-羟基-2-脱氧鸟苷和丙二醛水平、激活的巨噬细胞和细胞因子转化生长因子-β1 水平。在照射后 1-14 周给予卡托普利和 EUK-207 联合治疗后,几乎完全缓解了这些放射性效应。
卡托普利和 EUK-207 可提供至少 32 周 PI 的放射性肺损伤缓解,治疗时间为 1-14 周 PI。总的来说,卡托普利和 EUK-207 的联合使用比单独使用两种药物更有效。